Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Universal Biotech Co Ltd
SZSE:301166
|
CN |
|
Sanchuan Wisdom Technology Co Ltd
SZSE:300066
|
CN |
|
Rushnet Inc
OTC:RSHN
|
US |
|
Amcor PLC
NYSE:AMCR
|
UK |
|
Globalspace Technologies Ltd
BSE:540654
|
IN |
Adaptimmune Therapeutics PLC
Inventory
Adaptimmune Therapeutics PLC
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Inventory
$11.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Inventory
£6.7m
|
CAGR 3-Years
96%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Inventory
£74.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Inventory
£17.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
20%
|
|
Adaptimmune Therapeutics PLC
Glance View
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
See Also
What is Adaptimmune Therapeutics PLC's Inventory?
Inventory
11.4m
USD
Based on the financial report for Jun 30, 2025, Adaptimmune Therapeutics PLC's Inventory amounts to 11.4m USD.
